Journal of Clinical Oncology
Articles in this Issue
Obesity as a modifiable risk factor in familial adenomatous polyposis.
94 Background: Familial Adenomatous Polyposis (FAP) is a rare, autosomal dominant cancer syndrome caused by mutations in t...
Regorafenib combined with trifluridine/tipiracil versus regorafenib monotherapy in refractory metastatic colorectal cancer (FDZL-REGOT): A randomized phase 2 trial.
157 Background: For the third-line treatment of metastatic colorectal cancer (mCRC), the standard regimens of regorafenib...
Plasma GPC3 and its association with tumor GPC3 expression and clinical outcomes in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.
596 Background: Glypican‐3 (GPC3) is a membrane proteoglycan expressed in ~80% of hepatocellular carcinomas (HCC). In addi...
Too late to help? Disparities in palliative and hospice care among veterans with pancreatic cancer—A 10-year retrospective study at a VA medical center.
665 Background: Pancreatic cancer is characterized by high symptom burden, rapid progression, and poor prognosis. ASCO gui...
Long-term survival trends in GI cancer: Demographic and socioeconomic influences.
810 Background: Gastrointestinal (GI) cancers including esophageal, gastric, colorectal, hepatobiliary, and pancreatic mal...
Outcomes of sarcomatoid hepatocellular carcinoma patients treated with immunotherapy: A multi-institutional retrospective study.
569 Background: Sarcomatoid hepatocellular carcinoma (sHCC) is a rare and aggressive variant of HCC with poor prognosis. B...
Outcomes of epidermal growth factor receptor inhibitors in locally advanced and metastatic anal squamous cell carcinoma: A systematic review and meta-analysis.
10 Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy with limited systemic options. Epidermal growth fa...
Treatment of elderly patients with advanced pancreatic ductal adenocarcinoma utilizing a metronomic dose and schedule of chemotherapy.
726 Background: Pancreatic ductal adenocarcinoma (PDAC) is most prevalent in elderly patients, with a median age of 70 yea...
Impact of glucagon-like peptide-1 receptor agonists on clinical outcomes in pancreatic cancer: A large-scale real-world cohort study.
688 Background: Pancreatic cancer is one of the leading causes of cancer-related death and is associated with poor overall...
Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC).
TPS254 Background: Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is a direct-acting folate in development that may...
Incidence and risk factors of non-neutropenic enterocolitis with adjuvant capecitabine and oxaliplatin chemotherapy in colorectal cancer.
116 Background: Following the IDEA collaboration, the use of capecitabine and oxaliplatin (CAPOX regimen) for adjuvant col...
Safety outcomes with tremelimumab (T) rechallenge in the phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma.
541 Background: In HIMALAYA (NCT03298451), STRIDE (Single T Regular Interval D) improved overall survival vs sorafenib at...
Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma.
426 Background: The prognosis for advanced gastroesophageal adenocarcinoma (GEA) remains poor, highlighting the urgent nee...
Genetic configurations and liver niche drive tumor-intrinsic state plasticity in metastatic MSS-CRC.
190 Background: Microsatellite stable colorectal cancer (MSS-CRC) in advanced-stage disease remains a major therapeutic ch...
Treatment outcomes of patients with m <i>IDH1</i> cholangiocarcinoma in the United States.
507 Background: Cholangiocarcinoma (CCA), categorized as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA), is often...
Patterns in advanced radiation technique use and survival for pancreatic ductal adenocarcinoma and neuroendocrine tumors: Insights from the NCDB (2004-2022).
671 Background: Pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (pNET) encompass the predomina...
Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.
360 Background: Fruquintinib (FRU), a selective VEGFR 1/2/3 inhibitor, showed a significant PFS benefit in the phase 3 FRU...
Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).
654 Background: KRAS G12D is the mos...
Use of tumor-intrinsic pathways to identify novel targets in immune-cold esophagogastric adenocarcinoma.
451 Background: In first-line E/GEJ/G adenocarcinoma, anti-PD-1 + chemotherapy improves outcomes, yet many patients do not...
Radiofrequency ablation versus stereotactic body radiation therapy for early stage hepatocellular carcinoma: A propensity score matched analysis.
605 Background: Multiple treatment modalities are available for localized hepatocellular carcinoma (HCC), and current Barc...
Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study.
124 Background: The every-two-weeks (Q2W) dosing schedule of cetuximab plus fluorouracil-based agents is a commonly used m...
Predictors of long term survival from metastatic colorectal cancer: A single-centre Irish experience.
80 Background: In Ireland, 21% of colorectal cancers are metastatic at diagnosis, with 5-year-survival of 15%. Recent firs...
Age stratified IRAEs with immune checkpoint inhibitors in patients with metastatic gastric and colorectal cancer: Multicenter retrospective propensity matched analysis.
832 Background: Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment modality for metastatic gastric,...
Effects of soy food consumption in preventing hepatocellular carcinoma: A systematic review and meta-analysis.
526 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Soy contains isof...
Phase Ib/II study of ASP-1929 photoimmunotherapy (PIT) for esophageal cancer ineligible for curative standard therapies.
TPS474 Background: Esophageal squamous cell carcinoma (ESCC) remains a challenging malignancy, particularly for patients w...